Treace Medical Concepts Reports 1.6% Revenue Increase to $212.7 Million for Fiscal Year 2025

Treace Medical Concepts, Inc. reported a modest increase in revenue for the fiscal year ending December 31, 2025, with total revenue reaching $212.7 million, a 1.6% rise from $209.4 million in 2024. The growth was primarily driven by an increase in the number of bunion procedure kits sold, although this was partially offset by lower average selling prices for newer products. The company continues to face challenges, particularly with its flagship Lapiplasty System, which has seen declining sales due to evolving surgeon preferences for minimally invasive procedures and macroeconomic factors affecting patient demand for elective surgeries.

The company's cost of goods sold increased by 4.5% to $42.9 million, leading to a gross profit of $169.8 million and a gross margin of 79.8%. Operating expenses remained stable at approximately $223.9 million, with notable increases in general and administrative expenses, primarily due to ongoing litigation costs. The net loss for the year was $59.0 million, compared to a loss of $55.7 million in the previous year, reflecting a 5.8% increase in losses.

Strategically, Treace Medical has expanded its product offerings, including the introduction of the Nanoplasty and Percuplasty systems, which are designed for minimally invasive bunion correction. The company has also focused on enhancing its sales force and marketing efforts, with a field sales team of 297 members as of December 31, 2025. The number of active surgeons using Treace products increased by 6% to 3,337, indicating a growing adoption of its surgical systems.

Looking ahead, Treace Medical anticipates continued challenges from competitive pressures and changing market dynamics, particularly as more surgeries shift to ambulatory surgery centers, which typically offer lower reimbursement rates. The company is committed to investing in product innovation and expanding its market presence, but it acknowledges that macroeconomic conditions, including inflation and consumer sentiment, may impact future growth. The company has sufficient cash and marketable securities to fund operations for at least the next twelve months, but it may seek additional financing to support its growth initiatives.